Promoted Content
Promoted Content

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NXP004

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 19, 2020

            Details:

            NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RXC006

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: $377.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 04, 2020

            Details:

            Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ILR201104

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ILR201104

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: DynPort

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 06, 2020

            Details:

            The Immune Regulation entered into a Teaming Agreement with DynPort Vaccine Company LLC to jointly evaluate the potential of Immune Regulation’s drug product ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RXC007

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.